Abstracts Archive - Page 928 of 2425 - ACR Meeting Abstracts

Abstract Number: 2545 • 2019 ACR/ARP Annual Meeting
Belatacept in Systemic Lupus Erythematosus (SLE) Kidney Transplant Patients
Irene Carrión-Barberà ¹, Melissa Fajardo ², Demetra Tsapepas ², Cathy Guo ², Yevgeniya Gartshteyn ², Hilda Fernandez ² and Anca Askanase³, ¹CUMC, Barcelona, Spain, ²CUMC, New York, NY, ³Columbia University Medical Center, New York, NY
Background/Purpose: Lupus nephritis (LN) ultimately requires renal replacement therapy (RRT) in 10-30% of LN patients. Thirty percent of these patients receive a kidney transplant. Belatacept…
Abstract Number: 2546 • 2019 ACR/ARP Annual Meeting
Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial
Anca Askanase¹, Amit Saxena ², Aikaterini Thanou ³, Cristina Arriens ⁴, Debra J. Zack ⁵ and Joan Merrill ⁶, ¹Columbia University, New York, ²New York University Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Xencor, Inc., San Diego, CA, ⁶Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Measuring improvement or worsening is problematic in lupus trials. The British Isles Lupus Assessment Group (BILAG) index often fails to capture sustained decrease in…
Abstract Number: 2547 • 2019 ACR/ARP Annual Meeting
Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use
Anca Askanase¹, Dharani Munirathinam ², Enxu Zhao ², Julie Zhu ², Erin Connolly-Strong ² and Richard Furie ³, ¹Columbia University Medical Center, New York, NY, ²Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ³Northwell Health, Great Neck, NY
Background/Purpose: Repository corticotropin injection (RCI) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH1-39) analogues and other pituitary peptides that stimulates endogenous corticosteroid (CS)…
Abstract Number: 2548 • 2019 ACR/ARP Annual Meeting
Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity
Aikaterini Thanou¹, Cristina Arriens ², Teresa Aberle ¹, Heather Miller ¹, Lydia Mitchell ³, Stan Kamp ¹, Anca Askanase ⁴, Stavros Stavrakis ⁵, Judith James ² and Joan T. Merrill ⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Columbia University, New York, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, ⁶Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Abatacept (ABA) is a fusion protein of the extracellular domain of CTLA4 and human IgG1-Fc, constructed to inhibit B/T cell co-stimulation. Previous studies of…
Abstract Number: 2549 • 2019 ACR/ARP Annual Meeting
Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials
Maria Pitsui ¹, Orestis Papasouliotis², Colm Farrell ¹, Pascal Girard ², Oezkan Yalkinoglu ³ and Cristina Vazquez-Mateo ⁴, ¹ICON Plc, Dublin, Ireland, ²Merck Institute for Pharmacometrics, Lausanne, Switzerland, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono Research and Development Institute, Inc., Billerica, MA
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL and has been shown to reduce SLE disease activity. The aim of the analysis was…
Abstract Number: 2550 • 2019 ACR/ARP Annual Meeting
Impact of Pathogenic and Protective Environmental Exposures on Autoimmune Disease—The Microbiome Effects on Lupus (MEL) Study
Hayley Walter¹, Trevor Faith ², Alexander Alekseyenko ³, Ali Bakhtiari ³, Paula Ramos ² and Diane Kamen ⁴, ¹Division of Rheumatology/Medical University South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Medical University South Carolina, Charleston, SC, ⁴Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic and often severe multi-organ autoimmune disease characterized by the production of autoantibodies and heterogeneous clinical manifestations. African…
Abstract Number: 2551 • 2019 ACR/ARP Annual Meeting
Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Tests (CAT) in a Canadian Cohort of Patients with Systemic Lupus Erythematosus
Mitra Moazzami¹, Lisa Engel ², Nicole Anderson ³, Jiandong Su ³, Dennisse Bonilla ³, Pooneh Akhavan ⁴, Patricia Katz ⁵, Dorcas Beaton ⁶ and Zahi Touma ⁷, ¹George Washington University, Washington, DC, ²University of Manitoba, Winnipeg, MB, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, Canada, ⁵University of California, San Francisco, san francisco, CA, ⁶St. Michael's Hospital, Toronto, ON, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Patient-reported outcome measures are invaluable tools in clinical practice and are central in providing patient-centered care. There has been minimal research on the use…
Abstract Number: 2552 • 2019 ACR/ARP Annual Meeting
Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Sarah Gilman ¹, Deborah Levesque ², Carol Cummins ³, Daniel Wallace ⁴, Victoria Werth ⁵ and Patricia Davidson⁶, ¹Wayfinder Health Strategies, Washington, DC, ²Pro-Change Behavior Systems, Providence, RI, ³Pro-Change Behavior Systems, Inc.,, Providence, ⁴Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁵Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Lupus Foundation of America, Washington, DC
Background/Purpose: The Lupus Foundation of America is in Year 4 of a 6-year cooperative agreement with the Centers for Disease Control and Prevention to develop…
Abstract Number: 2553 • 2019 ACR/ARP Annual Meeting
Prescription Opioid Use and Osteoporotic Fractures in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Emily Somers¹, Sioban Harlow ¹, Nina Zhou ¹, Lu Wang ¹, Kamil Barbour ², Charles Helmick ³, Caroline Gordon ⁴, Deeba Minhas ¹, Beth Wallace ¹, Afton Hassett ¹, Suzanna Zick ¹, W. Joseph McCune ⁵ and Wendy Marder ¹, ¹University of Michigan, Ann Arbor, ²Centers for Disease Control and Prevention, Atlanta, ³Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: We recently reported prescription opioid use in nearly one-third of systemic lupus erythematosus (SLE) patients in our population-based cohort. Data suggest that opioids may…
Abstract Number: 2554 • 2019 ACR/ARP Annual Meeting
Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?
Konstantinos Tselios¹, Dafna Gladman ², Jiandong Su ³ and Murray Urowitz ¹, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus Low Disease Activity State (LLDAS) has been associated with favourable outcomes in systemic lupus erythematosus (SLE). However, the complexity of its defining criteria…
Abstract Number: 2555 • 2019 ACR/ARP Annual Meeting
Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients
Konstantinos Tselios¹, Dafna Gladman ², Shadi Akhtari ³, Paula Harvey ³, Kate Hanneman ⁴ and Murray Urowitz ⁵, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial-induced cardiomyopathy (AMIC) is a hypertrophic cardiomyopathy with conduction system disorders, cardiac biomarker abnormalities and a short-term mortality of 45%. Data on the reversibility…
Abstract Number: 2556 • 2019 ACR/ARP Annual Meeting
Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN
Ana Malvar¹, Valeria Alberton ², Cecilia Recalde ², Sheng Gao ³ and Michael Maldonado ³, ¹Hospital Fernandez; Organización Maedica de Investigación, Buenos Aires, Argentina, ²Hospital Fernandez, Buenos Aires, Argentina, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Current therapeutic management of active Class III or IV proliferative LN relies on the use of maintenance therapy following induction. The optimal method for…
Abstract Number: 2557 • 2019 ACR/ARP Annual Meeting
Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes – Case Control Study
Abdulrahman Alrashid¹, Yih Jia Poh ², David D'Cruz ³, Shirish Sangle ⁴, David McGibbon ⁵, Emma Benton ⁶ and Eleanor Higgins ⁵, ¹King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia, ²Singapore General Hospital, Singapore, Singapore, ³The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom, ⁴Guy's & St Thomas' Hospitals NHS Foundation Trust, London, England, United Kingdom, ⁵Guy's and St Thomas Foundation Trust, London, United Kingdom, ⁶Guy's and t Thomas Foundation Trust, London, United Kingdom
Background/Purpose: Drug induced subacute cutaneous lupus erythematosus has rarely been described. There is a growing literature reporting the association between proton pump inhibitor (PPI) use…
Abstract Number: 2558 • 2019 ACR/ARP Annual Meeting
Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616
R Andrea Fan¹, Janet Anderl ¹, Brian Tuch ², Darrin Bomba ¹, Niti Goel ³ and Christopher Kirk ¹, ¹Kezar Life Sciences, South San Francisco, CA, ²Kezar Life Sciences, south san francisco, ³Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: KZR-616 is a selective inhibitor of the immunoproteasome, the form of proteasome found predominantly in immune cells. In nonclinical studies, KZR-616 blocks acute production…
Abstract Number: 2559 • 2019 ACR/ARP Annual Meeting
A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus
W. Winn Chatham ¹, Richard Furie ², Amit Saxena ³, Philip Brohawn ⁴, Erik Schwetje⁵, Gabriel Abreu ⁶ and Raj Tummala ⁵, ¹University of Alabama Medical Center, Birmingham, AL, ²Zucker School of Medicine at Hofstra/Northwell, New York, NY, ³NYU Langone Orthopedic Center, New York, ⁴AstraZeneca, Gaithersburg, MD, ⁵AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, ⁶AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Anifrolumab is a fully human, IgG1κ monoclonal antibody that binds to the type I IFN receptor and inhibits activity of all type I IFNs.1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].